Correction of IVS I-110(G>A) β-thalassemia by CRISPR/Cas- and TALEN-mediated disruption of aberrant regulatory elements in human hematopoietic stem and progenitor cells

HAEMATOLOGICA

FERRATA STORTI FOUNDATION

1. Republic of Cyprus through the Research Promotion Foundation [YFEIA/BIOSigma/0311(BE)/20]
2. Cyprus Institute of Neurology and Genetics
3. TELETHON of Cyprus
4. Eurobank Cyprus Ltd [33173114]
5. European Union [306201]
6. German Federal Ministry of Education and Research [BMBF-01EO0803]
7. Hellenic Society of Gene Therapy and Regenerative Medicine